ArticleFrontiers in genetics2026
Screening of glucose-6-phosphate dehydrogenase deficiency in a cohort of 215,137 newborns: an epidemiological and pathogenic variant spectrum study in Yueyang, China.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a prevalent inherited metabolic disorder, affecting approximately 500 million individuals worldwide. Current neonatal screening protocols necessitate continuous refinement of cut-off values based on gestational age, birth weight, and seasonal variation. Genetic characterization of G6PD deficiency has become a critical component of newborn screening programs; however, the spectrum of pathogenic variants in the Yueyang region remains elusive. Methods: G6PD enzymatic activity was quantitatively assessed using fluorescence analysis of dried blood spot samples. Infants with abnormal results were recalled for targeted genetic testing focusing on known hotspot mutations. Results: A total of 215,137 newborns in Yueyang city underwent screening for G6PD deficiency, yielding an estimated overall birth prevalence of 4.77‰. Gestational age showed a consistent, independent negative correlation with G6PD enzymatic activity. The optimal cut-off value for male newborns was adjusted from 2.6 U/g Hb to 3.2 U/g Hb during winter. In total, 336 neonates were confirmed through the genetic diagnosis of G6PD deficiency. The most frequent pathogenic variant was c.1376G>T, accounting for 31.85% of cases, followed by c.1388G>A (22.92%), c.1311C>T (14.88%), c.95A>G (9.82%), c.1024C>T (8.33%), and c.871G>A (6.85%). The c.1376G>T mutation was associated with the greatest reduction in enzymatic activity, with median levels of 0.8 U/g Hb in males and 3.54 U/g Hb in females. Conclusion: Stratified by gestational age and seasonal variation, cut-off value optimization is essential for ensuring the efficacy of neonatal G6PD deficiency screening. This study primarily focuses on identifying asymptomatic G6PD deficiency and preventing severe hyperbilirubinemia and neurologic damage. Early screening, timely identification, and standardized follow-up should be prioritized to facilitate the implementation of eugenics-related public health strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.